Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | CPB1 | P15086 | 2/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | PTPRA | P18433 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23118112 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CPB2TBXAS1CPB1OR51E2 | |
| SCHEMBL23118113 | 1.00 | ALDH1A1 (0.37) | ALDH1A1CPB2TBXAS1CPB1OR51E2 | |
| SCHEMBL23139176 | 0.81 | KMT2A (0.36) | ALDH1A1CPB2CPB1 | |
| SCHEMBL4298196 | 0.77 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL20713602 | 0.75 | MEN1 (0.30) | ALDH1A1 | |
| SCHEMBL23118151 | 0.69 | ALDH1A1 (0.37) | ALDH1A1OR51E2KMOPTPRA | |
| SCHEMBL23118092 | 0.69 | GABRD (0.34) | ALDH1A1OR51E2KMOPTPRA | |
| SCHEMBL23118091 | 0.69 | GABRD (0.34) | ALDH1A1OR51E2KMOPTPRA | |
| SCHEMBL23118150 | 0.69 | ALDH1A1 (0.37) | ALDH1A1OR51E2KMOPTPRA | |
| SCHEMBL24329784 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| CN-111356680-A | Selective inhibitors of NLRP3inflammasome | 诺瑟拉有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | ALDH1A1 961/4885CPB2 3315/4885TBXAS1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.